These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36058929)

  • 1. Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer.
    Wu C; Qiu Y; Zhang R; Li X; Liang H; Wang M; Li F; Zhu M; Ye G; Liu H; Li G; Zhao L
    J Transl Med; 2022 Sep; 20(1):386. PubMed ID: 36058929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients.
    He X; Cao Y; Gu Y; Fang H; Wang J; Liu X; Lv K; Yu K; Fei Y; Lin C; Liu H; Zhang H; Li H; Xu J; Li R; He H
    Ann Surg Oncol; 2021 Oct; 28(11):6439-6450. PubMed ID: 33738713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-infiltrating M2 macrophage in pretreatment biopsy sample predicts response to chemotherapy and survival in esophageal cancer.
    Yamamoto K; Makino T; Sato E; Noma T; Urakawa S; Takeoka T; Yamashita K; Saito T; Tanaka K; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Mori M; Doki Y; Wada H
    Cancer Sci; 2020 Apr; 111(4):1103-1112. PubMed ID: 31981293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer.
    Tang X; Li M; Wu X; Guo T; Zhang L; Tang L; Jia F; Hu Y; Zhang Y; Xing X; Shan F; Gao X; Li Z
    Oncoimmunology; 2022; 11(1):2135819. PubMed ID: 36268179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
    Alessi JV; Ricciuti B; Alden SL; Bertram AA; Lin JJ; Sakhi M; Nishino M; Vaz VR; Lindsay J; Turner MM; Pfaff K; Sharma B; Felt KD; Rodig SJ; Gainor JF; Awad MM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-1 plus anti-angiogenesis combined with chemotherapy in patients with HER2-negative advanced or metastatic gastric cancer: a multi-institutional retrospective study.
    Xu T; Wang W; Bao R; Xia X; Zhang J; Huang M; Chen X; Wang R; Zhang H; Liu X; Li Q; Shu Y
    J Gastrointest Oncol; 2023 Feb; 14(1):175-186. PubMed ID: 36915465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: A retrospective study.
    Guo J; Zhou Q; Zhou M; Dai H; Li L; Qiu Y; Mao L; Liu B; Shen J
    Cancer Med; 2023 Nov; 12(22):20699-20711. PubMed ID: 37930138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy is linked to an amended anti-tumorigenic microenvironment in gastric cancer.
    Huan X; Zou K; Zhang P; Ding H; Luo C; Xiang C; Xu S; Zhuang Y; Wu C; Wang Y; Wu X; Chen C; Zhang J; Yao X; Liu F; Liu S; Wu Z
    Int Immunopharmacol; 2024 Jan; 127():111352. PubMed ID: 38091833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
    BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
    Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
    J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
    Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
    J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 13. PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis.
    Guo X; Yang B; He L; Sun Y; Song Y; Qu X
    Front Immunol; 2022; 13():905651. PubMed ID: 36003374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of tumor-infiltrating CD163
    Kinoshita J; Fushida S; Yamaguchi T; Moriyama H; Saito H; Shimada M; Terai S; Okamoto K; Nakamura K; Ninomiya I; Yagi S; Inaki N
    BMC Cancer; 2022 Jun; 22(1):608. PubMed ID: 35658848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
    Li LH; Chen WC; Wu G
    Dis Markers; 2022; 2022():4322404. PubMed ID: 35531474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
    JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive response and outcome of peripheral CD4
    Gao D; Liu L; Liu J; Liu J
    Int Immunopharmacol; 2024 Mar; 129():111663. PubMed ID: 38364744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
    Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
    Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.